Latest Jan Burger Stories
Ibrutinib, rituximab deliver a 1-2 punch to patients with few good options A two-prong approach combining ibrutinib and rituximab (Rituxin®) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center. Researchers presented the results today at the 54th annual meeting of the American Society of Hematology (ASH). "This is a patient population with a great...
- The offense of persistently instigating lawsuits, typically groundless ones.
- An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
- Sale or purchase of positions in church or state.